雅培2026Q3营收130.13亿美元、调整后EPS $1.42，维持全年EPS指引中点但下调可比销售增速指引

----- abt-20261021.htm -----
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
_______________________________________________________
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 21, 2026
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
_______________________________________________________
Illinois
1-2189
36-0698440
(State or other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification  No.)
_______________________________________________________
100 Abbott Park Road
Abbott Park
,
Illinois
60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:
(
224
)
667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class
Trading
Symbol(s)
Name of Each Exchange
on Which Registered
Common Shares, Without Par Value
ABT
New York Stock Exchange
NYSE Texas
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 2.02    Results of Operations and Financial Condition
On October 21, 2026,
Abbott Laboratories announced its results of operations for the third quarter 2026.
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, legal settlements, stock-based compensation recognized as expense from equity awards accelerated in connection with an acquisition, restructuring actions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01    Financial Statements and Exhibits
Exhibit No.
Exhibit
99.1
Press Release dated October 21, 2026 (furnished pursuant to Item 2.02).
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBOTT LABORATORIES
Date: October 21, 2026
By:
/s/ Philip P. Boudreau
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer

----- abt-2026q3xexhibitx991.htm -----
EX-99.1
2
abt-2026q3xexhibitx991.htm
EX-99.1
Document
Exhibit 99.1
News Release
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
–
Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent
–
Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42
–
Expands portfolio with key new product approvals
ABBOTT PARK, Ill., Oct. 21, 2026 — Abbott today announced financial results for the third quarter ended Sept. 30, 2026.
•
Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis.
•
Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items.
•
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent
1
.
•
Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55.
•
In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
•
In August, Abbott announced that the company received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib).
•
In August, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk — the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States.
•
In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation.
•
In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease.
"Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead."
Page 1 of 21
THIRD-QUARTER BUSINESS OVERVIEW
Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions)
Total Company
Nutrition
Diagnostics
Established Pharmaceuticals
Medical Devices
U.S.
5,504
958
1,853
—
2,687
International
7,509
1,304
1,452
1,614
3,139
Total reported
13,013
2,262
3,305
1,614
5,826
% Change vs. 3Q25
U.S.
28.0
7.9
109.2
n/a
6.6
International
6.2
3.1
6.2
6.8
7.2
Total reported
14.5
5.1
46.7
6.8
6.9
Total reported excl. foreign exchange impact
14.8
4.9
46.6
8.4
7.4
Comparable sales growth
7.0
4.9
6.4
8.4
7.8
U.S.
7.9
7.9
8.4
n/a
7.6
International
6.4
2.8
4.0
8.4
8.0
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions)
Total Company
Nutrition
Diagnostics
Established Pharmaceuticals
Medical Devices
U.S.
14,994
2,673
4,418
—
7,890
International
21,776
3,750
4,159
4,539
9,328
Total reported
36,770
6,423
8,577
4,539
17,218
% Change vs. 9M25
U.S.
17.7
(4.5)
72.0
n/a
7.1
International
8.2
1.1
6.3
9.3
11.7
Total reported
11.9
(1.3)
32.4
9.3
9.6
Total reported excl. foreign exchange impact
10.5
(2.1)
30.8
8.7
7.8
Comparable sales growth
5.2
(2.1)
3.8
8.7
8.2
U.S.
4.7
(4.5)
4.9
n/a
8.1
International
5.7
(0.3)
2.4
8.7
8.3
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 2 of 21
Nutrition
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions)
Total
Pediatric
Adult
U.S.
958
577
381
International
1,304
486
818
Total reported
2,262
1,063
1,199
% Change vs. 3Q25
U.S.
7.9
11.0
3.5
International
3.1
6.4
1.3
Total reported
5.1
8.8
2.0
Total reported excl. foreign exchange impact
4.9
8.7
1.8
Comparable sales growth
4.9
8.7
1.8
U.S.
7.9
11.0
3.5
International
2.8
6.0
1.0
Worldwide Nutrition sales increased 5.1 percent on a reported basis and 4.9 percent on a comparable basis in the third quarter.
Worldwide Nutrition results were driven by broad-based growth across the portfolio, including sales growth of nearly 9.0 percent in Worldwide Pediatric.
On a sequential basis, Worldwide Nutrition sales increased $118 million compared to the second quarter of 2026.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions)
Total
Pediatric
Adult
U.S.
2,673
1,613
1,060
International
3,750
1,428
2,322
Total reported
6,423
3,041
3,382
% Change vs. 9M25
U.S.
(4.5)
(4.8)
(4.0)
International
1.1
3.7
(0.5)
Total reported
(1.3)
(1.0)
(1.6)
Total reported excl. foreign exchange impact
(2.1)
(1.6)
(2.6)
Comparable sales growth
(2.1)
(1.6)
(2.6)
U.S.
(4.5)
(4.8)
(4.0)
International
(0.3)
2.4
(2.0)
Page 3 of 21
Diagnostics*
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions)
Total
Core Laboratory
Cancer Diagnostics
Rapid/Molecular Diagnostics
U.S.
1,853
389
938
526
International
1,452
1,049
30
373
Total reported
3,305
1,438
968
899
% Change vs. 3Q25
U.S.
109.2
6.3
n/a
1.1
International
6.2
5.1
n/a
1.0
Total reported
46.7
5.4
n/a
1.1
Total reported excl. foreign exchange impact
46.6
5.4
n/a
0.9
Comparable sales growth
6.4
5.4
13.8
0.9
U.S.
8.4
6.3
13.9
1.1
International
4.0
5.1
12.1
0.7
Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter.
Worldwide Core Laboratory Diagnostics results were driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America.
Cancer Diagnostics results were driven by growth of Cologuard® and also reflect contributions to growth from the precision oncology and international businesses.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions)
Total
Core Laboratory
Cancer Diagnostics
Rapid/Molecular Diagnostics
U.S.
4,418
1,113
1,921
1,384
International
4,159
3,015
62
1,082
Total reported
8,577
4,128
1,983
2,466
% Change vs. 9M25
U.S.
72.0
6.1
n/a
(8.9)
International
6.3
5.8
n/a
1.9
Total reported
32.4
5.9
n/a
(4.5)
Total reported excl. foreign exchange impact
30.8
4.0
n/a
(5.4)
Comparable sales growth
3.8
4.0
13.5
(5.4)
U.S.
4.9
6.1
13.5
(8.9)
International
2.4
3.2
15.0
(0.4)
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 4 of 21
Established Pharmaceuticals
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions)
Total
Key Emerging Markets
Other
U.S.
—
—
—
International
1,614
1,195
419
Total reported
1,614
1,195
419
% Change vs. 3Q25
U.S.
n/a
n/a
n/a
International
6.8
9.0
1.1
Total reported
6.8
9.0
1.1
Total reported excl. foreign exchange impact
8.4
10.9
1.6
Comparable sales growth
8.4
10.9
1.6
U.S.
n/a
n/a
n/a
International
8.4
10.9
1.6
Established Pharmaceuticals sales increased 6.8 percent on a reported basis and 8.4 percent on a comparable basis in the third quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India and several markets across the Latin America and Asia Pacific regions.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions)
Total
Key Emerging Markets
Other
U.S.
—
—
—
International
4,539
3,448
1,091
Total reported
4,539
3,448
1,091
% Change vs. 9M25
U.S.
n/a
n/a
n/a
International
9.3
10.5
5.6
Total reported
9.3
10.5
5.6
Total reported excl. foreign exchange impact
8.7
10.4
3.6
Comparable sales growth
8.7
10.4
3.6
U.S.
n/a
n/a
n/a
International
8.7
10.4
3.6
Page 5 of 21
Medical Devices
Third Quarter 2026 Results (3Q26)
Sales 3Q26 ($ in millions)
Total
Rhythm Management
Electro-physiology*
Heart Failure
Vascular
Structural Heart*
Neuro-modulation
Diabetes Care
U.S.
2,687
380
429
303
290
228
185
872
International
3,139
372
444
84
496
364
66
1,313
Total reported
5,826
752
873
387
786
592
251
2,185
% Change vs. 3Q25
U.S.
6.6
9.0
18.1
8.4
3.4
(11.1)
(5.6)
9.4
International
7.2
10.4
12.2
(2.7)
6.7
12.2
13.6
4.2
Total reported
6.9
9.7
15.0
5.8
5.4
1.9
(1.2)
6.2
Total reported excl. foreign exchange impact
7.4
10.0
15.5
6.0
5.7
2.6
(1.1)
6.7
Comparable sales growth
7.8
10.0
15.5
6.0
5.7
6.9
(1.1)
6.7
U.S.
7.6
9.0
18.1
8.4
3.4
(2.3)
(5.6)
9.4
International
8.0
11.0
13.1
(1.6)
7.1
13.5
13.9
4.9
Worldwide Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis in the third quarter.
Sales growth in the quarter was led by double-digit growth in Electrophysiology and Rhythm Management.
In Diabetes Care, sales of continuous glucose monitors grew 7.3 percent on a reported basis and 7.7 percent on a comparable basis.
First Nine Months 2026 Results (9M26)
Sales 9M26 ($ in millions)
Total
Rhythm Management
Electro-physiology*
Heart Failure
Vascular
Structural Heart*
Neuro-modulation
Diabetes Care
U.S.
7,890
1,096
1,227
908
875
677
551
2,556
International
9,328
1,083
1,295
269
1,491
1,090
203
3,897
Total reported
17,218
2,179
2,522
1,177
2,366
1,767
754
6,453
% Change vs. 9M25
U.S.
7.1
10.4
16.0
10.2
5.2
(10.2)
(2.4)
9.3
International
11.7
13.9
14.5
7.9
8.0
16.1
18.1
10.5
Total reported
9.6
12.1
15.2
9.7
7.0
4.4
2.4
10.0
Total reported excl. foreign exchange impact
7.8
10.6
13.8
8.9
5.2
2.6
1.3
7.7
Comparable sales growth
8.2
10.6
13.8
8.9
5.2
6.5
1.3
7.7
U.S.
8.1
10.4
16.0
10.2
5.2
(2.3)
(2.4)
9.3
International
8.3
10.8
11.9
4.6
5.2
12.8
13.5
6.6
*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 and $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.
Refer to pages 16 and 17 for a reconciliation of comparable sales growth.
Page 6 of 21
Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0%
1
.
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.
Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.
Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.
Abbott Declares 411
th
Consecutive Quarterly Dividend
On Sept. 17, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.
Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.
Connect with us at
www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
Page 7 of 21
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott Financial:
Michael Comilla, 224-668-1872
Tamika McLoughlin, 224-399-5082
Randy Blakley, 224-668-0036
Abbott Media:
Karen Twigg May, 224-668-2681
Kate Dyer, 224-668-9965
1.
In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.
Page 8 of 21
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Third Quarter Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
3Q26
3Q25
% Change
Net Sales
$13,013
$11,369
14.5
Cost of products sold, excluding amortization expense
5,628
5,075
10.9
Amortization of intangible assets
841
420
n/m
Research and development
920
766
20.1
Selling, general, and administrative
4,266
3,051
39.8
Total Operating Cost and Expenses
11,655
9,312
25.2
Operating Earnings
1,358
2,057
(34.0)
Interest expense, net
297
44
n/m
Net foreign exchange (gain) loss
(6)
(17)
n/m
Other (income) expense, net
(164)
(150)
9.4
Earnings before taxes
1,231
2,180
(43.5)
Taxes on Earnings
311
536
(42.0)
1)
Net Earnings
$920
$1,644
(44.1)
Net Earnings excluding Specified Items, as described below
$2,477
$2,278
8.7
2)
Diluted Earnings per Common Share
$0.53
$0.94
(43.6)
Diluted Earnings per Common Share, excluding Specified Items, as described below
$1.42
$1.30
9.2
2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options
1,738
1,749
NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
Page 9 of 21
1)
2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)
2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.557 billion, or $0.89 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $634 million, or $0.36 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.
Page 10 of 21
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Nine Months Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
9M26
9M25
% Change
Net Sales
$36,770
$32,869
11.9
Cost of products sold, excluding amortization expense
15,843
14,397
10.0
Amortization of intangible assets
1,921
1,260
52.4
Research and development
2,579
2,207
16.9
Selling, general, and administrative
12,031
9,203
30.7
Total Operating Cost and Expenses
32,374
27,067
19.6
Operating Earnings
4,396
5,802
(24.2)
Interest expense, net
664
143
n/m
Net foreign exchange (gain) loss
(15)
(35)
n/m
Other (income) expense, net
(457)
(414)
10.2
Earnings before taxes
4,204
6,108
(31.2)
Taxes on earnings
1,279
1,360
(6.0)
1)
Net Earnings
$2,925
$4,748
(38.4)
Net Earnings excluding Specified Items, as described below
$6,789
$6,410
5.9
2)
Diluted Earnings per Common Share
$1.67
$2.70
(38.1)
Diluted Earnings per Common Share,
excluding Specified Items, as described below
$3.88
$3.65
6.3
2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
1,743
1,749
NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
Page 11 of 21
1)
2026 Taxes on Earnings includes the recognition of approximately
$95
million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026
Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit
.
2)
2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $3.864 billion, or $2.21 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.
2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.
Page 12 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Third Quarter Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
3Q26
As Reported (GAAP)
Specified Items
As Adjusted
Intangible Amortization
$
841
$
(841)
$
—
Gross Margin
6,544
904
7,448
R&D
920
(28)
892
SG&A
4,266
(761)
3,505
Other (income) expense, net
(164)
4
(160)
Earnings before taxes
1,231
1,689
2,920
Taxes on Earnings
311
132
443
Net Earnings
920
1,557
2,477
Diluted Earnings per Share
$
0.53
$
0.89
$
1.42
Specified items reflect intangible amortization expense of $841 million, legal settlements of approximately $670 million and other net expenses of $178 million associated with acquisitions, restructuring actions, and other net expenses. See page 18 for additional details regarding specified items.
3Q25
As Reported (GAAP)
Specified Items
As Adjusted
Intangible Amortization
$
420
$
(420)
$
—
Gross Margin
5,874
470
6,344
R&D
766
(36)
730
SG&A
3,051
(47)
3,004
Other (income) expense, net
(150)
5
(145)
Earnings before taxes
2,180
548
2,728
Taxes on Earnings
536
(86)
450
Net Earnings
1,644
634
2,278
Diluted Earnings per Share
$
0.94
$
0.36
$
1.30
Specified items reflect intangible amortization expense of $420 million and other net expenses of $128 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See page 19 for additional details regarding specified items.
Page 13 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Nine Months Ended September 30, 2026 and 2025
(in millions, except per share data)
(unaudited)
9M26
As
Reported (GAAP)
Specified Items
As
Adjusted
Intangible Amortization
$
1,921
$
(1,921)
$
—
Gross Margin
19,006
2,033
21,039
R&D
2,579
(77)
2,502
SG&A
12,031
(1,662)
10,369
Other (income) expense, net
(457)
(30)
(487)
Earnings before taxes
4,204
3,802
8,006
Taxes on Earnings
1,279
(62)
1,217
Net Earnings
2,925
3,864
6,789
Diluted Earnings per Share
$
1.67
$
2.21
$
3.88
Specified items reflect intangible amortization expense of $1.921 billion, legal settlements of approximately $1.070 billion and other net expenses of $811 million associated with acquisitions, restructuring actions, and other net expenses. See page 20 for additional details regarding specified items.
9M25
As
Reported (GAAP)
Specified Items
As
Adjusted
Intangible Amortization
$
1,260
$
(1,260)
$
—
Gross Margin
17,212
1,396
18,608
R&D
2,207
(83)
2,124
SG&A
9,203
(58)
9,145
Other (income) expense, net
(414)
(31)
(445)
Earnings before taxes
6,108
1,568
7,676
Taxes on Earnings
1,360
(94)
1,266
Net Earnings
4,748
1,662
6,410
Diluted Earnings per Share
$
2.70
$
0.95
$
3.65
Specified items reflect intangible amortization expense of $1.260 billion and other net expenses of $308 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See page 21 for additional details regarding specified items.
Page 14 of 21
A reconciliation of the third-quarter tax rates for 2026 and 2025 is shown below:
3Q26
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$
1,231
$
311
25.3
%
1)
Specified items
1,689
132
Excluding specified items
$
2,920
$
443
15.2
%
3Q25
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$
2,180
$
536
24.6
%
2)
Specified items
548
(86)
Excluding specified items
$
2,728
$
450
16.5
%
1)
2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)
2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below:
9M26
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$
4,204
$
1,279
30.4
%
3)
Specified items
3,802
(62)
Excluding specified items
$
8,006
$
1,217
15.2
%
9M25
($ in millions)
Pre-Tax
Income
Taxes on
Earnings
Tax
Rate
As reported (GAAP)
$
6,108
$
1,360
22.3
%
4)
Specified items
1,568
(94)
Excluding specified items
$
7,676
$
1,266
16.5
%
3)
2026 Taxes on Earnings includes the recognition of approximately
$95
million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026
Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
4)
2025
Taxes on Earnings includes the recognition of approximately
$90
million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025
Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 15 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Third Quarter Ended September 30, 2026 and 2025
($ in millions)
(unaudited)
3Q26
3Q25
% Change vs. 3Q25
Non-GAAP
Abbott Reported
Foreign exchange
Comparable Revenue
Abbott Reported
Impact of acquisition (a)
Impact
of multi-year agreement (b)
Comparable Revenue
Reported
Comparable
Total Company
13,013
40
13,053
11,369
851
(23)
12,197
14.5
7.0
U.S.
5,504
—
5,504
4,299
824
(23)
5,100
28.0
7.9
Intl
7,509
40
7,549
7,070
27
—
7,097
6.2
6.4
Total Diagnostics
3,305
(2)
3,303
2,253
851
—
3,104
46.7
6.4
U.S.
1,853
—
1,853
886
824
—
1,710
109.2
8.4
Intl
1,452
(2)
1,450
1,367
27
—
1,394
6.2
4.0
Total Cancer Diagnostics
968
—
968
—
851
—
851
n/a
13.8
U.S.
938
—
938
—
824
—
824
n/a
13.9
Intl
30
—
30
—
27
—
27
n/a
12.1
Total Medical Devices
5,826
22
5,848
5,448
—
(23)
5,425
6.9
7.8
U.S.
2,687
—
2,687
2,521
—
(23)
2,498
6.6
7.6
Intl
3,139
22
3,161
2,927
—
—
2,927
7.2
8.0
Total Structural Heart*
592
4
596
580
—
(23)
557
1.9
6.9
U.S.
228
—
228
256
—
(23)
233
(11.1)
(2.3)
Intl
364
4
368
324
—
—
324
12.2
13.5
*
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 were moved from Structural Heart to Electrophysiology.
a)
The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b)
Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Page 16 of 21
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Nine Months Ended September 30, 2026 and 2025
($ in millions)
(unaudited)
9M26
9M25
% Change vs. 9M25
Non-GAAP
Abbott Reported
Impact of acquisition (a)
Impact
of multi-year agreement (b)
Foreign exchange
Comparable Revenue
Abbott Reported
Impact of acquisition (a)
Impact
of multi-year agreement (b)
Comparable Revenue
Reported
Comparable
Total Company
36,770
706
(8)
(460)
37,008
32,869
2,369
(69)
35,169
11.9
5.2
U.S.
14,994
681
(8)
—
15,667
12,743
2,294
(69)
14,968
17.7
4.7
Intl
21,776
25
—
(460)
21,341
20,126
75
—
20,201
8.2
5.7
Total Diagnostics
8,577
706
—
(100)
9,183
6,480
2,369
—
8,849
32.4
3.8
U.S.
4,418
681
—
—
5,099
2,568
2,294
—
4,862
72.0
4.9
Intl
4,159
25
—
(100)
4,084
3,912
75
—
3,987
6.3
2.4
Total Cancer Diagnostics
1,983
706
—
(1)
2,688
—
2,369
—
2,369
n/a
13.5
U.S.
1,921
681
—
—
2,602
—
2,294
—
2,294
n/a
13.5
Intl
62
25
—
(1)
86
—
75
—
75
n/a
15.0
Total Medical Devices
17,218
—
(8)
(284)
16,926
15,712
—
(69)
15,643
9.6
8.2
U.S.
7,890
—
(8)
—
7,882
7,363
—
(69)
7,294
7.1
8.1
Intl
9,328
—
—
(284)
9,044
8,349
—
—
8,349
11.7
8.3
Total Structural Heart*
1,767
—
(8)
(31)
1,728
1,692
—
(69)
1,623
4.4
6.5
U.S.
677
—
(8)
—
669
753
—
(69)
684
(10.2)
(2.3)
Intl
1,090
—
—
(31)
1,059
939
—
—
939
16.1
12.8
*
Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.
a)
The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.
b)
Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Page 17 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Third Quarter Ended September 30, 2026
(in millions, except per share data)
(unaudited)
Acquisition or Divestiture- related (a)
Restructuring and Cost Reduction Initiatives (b)
Intangible Amortization
Other (c)
Total Specifieds
Gross Margin
$
10
$
29
$
841
$
24
$
904
R&D
(7)
(5)
—
(16)
(28)
SG&A
(47)
(20)
—
(694)
(761)
Other (income) expense, net
(8)
(1)
—
13
4
Earnings before taxes
$
72
$
55
$
841
$
721
1,689
Taxes on Earnings (d)
132
Net Earnings
$
1,557
Diluted Earnings per Share
$
0.89
The table above provides additional details regarding the specified items described on page 13.
a)
Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.
c)
Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants, as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)
Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 18 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Third Quarter Ended September 30, 2025
(in millions, except per share data)
(unaudited)
Acquisition or Divestiture- related (a)
Restructuring and Cost Reduction Initiatives (b)
Intangible Amortization
Other (c)
Total Specifieds
Gross Margin
$
—
$
44
$
420
$
6
$
470
R&D
—
(19)
—
(17)
(36)
SG&A
(9)
(43)
—
5
(47)
Other (income) expense, net
7
—
—
(2)
5
Earnings before taxes
$
2
$
106
$
420
$
20
548
Taxes on Earnings (d)
(86)
Net Earnings
$
634
Diluted Earnings per Share
$
0.36
The table above provides additional details regarding the specified items described on page 13.
a)
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)
Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)
Reflects the net tax benefit associated with the specified items. Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 19 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Nine Months Ended September 30, 2026
(in millions, except per share data)
(unaudited)
Acquisition or Divestiture- related (a)
Restructuring and Cost Reduction Initiatives (b)
Intangible Amortization
Other (c)
Total Specifieds
Gross Margin
$
44
$
40
$
1,921
$
28
$
2,033
R&D
(18)
(15)
—
(44)
(77)
SG&A
(533)
(54)
—
(1,075)
(1,662)
Other (income) expense, net
(9)
(4)
—
(17)
(30)
Earnings before taxes
$
604
$
113
$
1,921
$
1,164
3,802
Taxes on Earnings (d)
(62)
Net Earnings
$
3,864
Diluted Earnings per Share
$
2.21
The table above provides additional details regarding the specified items described on page 14.
a)
Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c)
Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the NEC claims asserted on behalf of approximately 2,000 additional infants; approximately $400 million, including attorneys' fees and accrued interest, related to an agreement to resolve the United States Department of Justice (DOJ) investigations and the civil qui tam lawsuit brought by certain relators and joined by the DOJ and Attorneys General of several states; as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)
Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 20 of 21
Abbott Laboratories and Subsidiaries
Details of Specified Items
Nine Months Ended September 30, 2025
(in millions, except per share data)
(unaudited)
Acquisition or Divestiture- related (a)
Restructuring and Cost Reduction Initiatives (b)
Intangible Amortization
Other (c)
Total Specifieds
Gross Margin
$
1
$
125
$
1,260
$
10
$
1,396
R&D
(1)
(42)
—
(40)
(83)
SG&A
(15)
(49)
—
6
(58)
Other (income) expense, net
(18)
—
—
(13)
(31)
Earnings before taxes
$
35
$
216
$
1,260
$
57
1,568
Taxes on Earnings (d)
(94)
Net Earnings
$
1,662
Diluted Earnings per Share
$
0.95
The table above provides additional details regarding the specified items described on page 14.
a)
Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)
Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)
Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.
d)
Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
Page 21 of 21